Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02159's Return-on-Tangible-Equity is ranked better than 87.33% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.605
vs HKSE:02159: 174.79
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mediwelcome Healthcare Management & Technology Return-on-Tangible-Equity Related Terms
Mediwelcome Healthcare Management & Technology Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02159 vs VEEV, BTSG, HQY: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mediwelcome Healthcare Management & Technology Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 38.93% mean?
Mediwelcome Healthcare Management & Technology (HKSE:02159) has a Return-on-Tangible-Equity of 38.93% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. This is 233% above median its historical median of 11.70. According to the industry distribution chart, Mediwelcome Healthcare Management & Technology ranks #73 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 12.7%.
Is Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Equity too high?
Mediwelcome Healthcare Management & Technology's current Return-on-Tangible-Equity of 38.93% is 233% above median its 10-year median of 11.70. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.61. Mediwelcome Healthcare Management & Technology's value of 38.93% is 267.1% above this industry median. Based on the distribution chart, Mediwelcome Healthcare Management & Technology ranks #73 out of 576 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mediwelcome Healthcare Management & Technology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mediwelcome Healthcare Management & Technology ranks #73 out of 576 companies for Return-on-Tangible-Equity. This places Mediwelcome Healthcare Management & Technology in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.61. Mediwelcome Healthcare Management & Technology's value of 38.93% is 267.1% above this benchmark. While the company's 10-year median is 11.70 vs. the industry median of 10.61, Mediwelcome Healthcare Management & Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.61, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mediwelcome Healthcare Management & Technology's current Return-on-Tangible-Equity of 38.93% is 267.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mediwelcome Healthcare Management & Technology's current Return-on-Tangible-Equity is 38.93%, which is 233% above median its own 10-year median of 11.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mediwelcome Healthcare Management & Technology stock overvalued right now?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology (HKSE:02159) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.70, compared to a current price of HK$1.78 — trading 154.3% above its estimated fair value. The current Return-on-Tangible-Equity is 38.93%, which is 233% above median its 10-year median of 11.70 and 267.1% above the Healthcare Providers & Services industry median of 10.61. Mediwelcome Healthcare Management & Technology's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Mediwelcome Healthcare Management & Technology (HKSE:02159), the current Return-on-Tangible-Equity is 38.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mediwelcome Healthcare Management & Technology (HKSE:02159) Overvalued in 2026?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology stock appears to be overvalued.
The current stock price of HK$1.78 is trading 154.3% above its estimated GF Value™ of HK$0.70.
GuruFocus considers Mediwelcome Healthcare Management & Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02159:
Return-on-Tangible-Equity: 38.93% (233% above median its 10-year median of 11.70)
GF Value™: HK$0.70 vs. price of HK$1.78 (154.3% above fair value)
Industry Position: 267.1% above the Healthcare Providers & Services median (#73 of 576)
No single metric tells the full story. See the HKSE:02159 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mediwelcome Healthcare Management & Technology Inc is an investment holding company. The Group mainly provides medical conference services, patient education and screening services, and marketing and consulting services, in addition to providing integrated healthcare marketing solutions. Its products and services include Academic Conference Management System, Scientific Research Data Reporting System, the Health/Medical Media Matrix, patient management services, and marketing and consulting services. The Group has only one reportable segment, mainly operating its businesses in the PRC and earning revenue from the PRC.
54GF Score
Get the complete analysis for HKSE:02159
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02159 has been successfully added to your 
